Swarthmore, PA, United States of America

Usman Shabon

This inventor holds 19 USPTO granted patents, primarily in G-Protein Coupled Receptors. Top assignees: Smithkline Beecham Corporation, Sb Laboratoires Pharmaceutiques, Other. Active years: 1998-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Usman Shabon. Retrieved from https://idiyas.com/inventor/usman-shabon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19

% Patents Active = 94.7

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Swarthmore, PA (US) (1998 - 2002)
Collegeville, PA (US) (2000 - 2005)

Company Filing History:

21 out of 2,198

Smithkline Beecham Corporation

patents

1 out of 1

Sb Laboratoires Pharmaceutiques

patent

1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2005

Loading Chart...

Areas of Expertise:

Molecular Cloning

7TM Receptor

Polynucleotides

G-Protein Coupled Receptor

Neurotensin

Protein Kinase

Membrane-Type Metalloproteinase

Agonist

Antagonist

Polypeptide

Nucleic Acid

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6881827 - Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof (2005-04-19),

2. 6461836 - Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof (2002-10-08),

3. 6428982 - Polynucleotides encoding mouse urotensin-II Receptor (UTB-R) (2002-08-06),

4. 6388055 - Mouse CC-CKR5 receptor polypeptide (2002-05-14),

5. 6297036 - YAK-1 related serine/threonine protein kinase-HTLAR33 (2001-10-02),

6. 6214600 - Membrane-type matrix metalloproteinase-5 gene (2001-04-10),

7. 6166182 - Human neurotensin receptor type 2 and splice variants thereof (2000-12-26),

8. 6159716 - Human protein kinase HOACF72 (2000-12-12),

9. 6159700 - Method of finding agonist and antagonist to human and rat GPR14 (2000-12-12),

10. 6133420 - GPR14 polypeptides (2000-10-17),

11. 6133006 - YAK-1 related serine/threonine protein kinase-HTLAR33 (2000-10-17),

12. 6071722 - Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1) (2000-06-06),

13. 6031090 - Molecular cloning of a 7TM receptor (GPR31A) (2000-02-29),

14. 6008050 - Human neurotensin receptor type 2 and splice variants thereof (1999-12-28),

15. 6005074 - Cloning of human GPR14 receptor (1999-12-21),

Title: The Innovative Mind of Usman Shabon

Introduction:

Usman Shabon, a talented inventor hailing from Swarthmore, PA, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

Usman Shabon's latest patents include a revolutionary smart home device that integrates artificial intelligence to enhance security measures and a cutting-edge wearable technology aimed at improving healthcare monitoring systems.

Career Highlights:

With a career spanning over two decades, Usman Shabon has consistently pushed the boundaries of technological advancement. His work has been instrumental in shaping the future of various industries, from healthcare to cybersecurity.

Collaborations:

Throughout his career, Usman Shabon has collaborated with leading tech companies, research institutions, and universities to bring his innovative ideas to life. His ability to work seamlessly in multidisciplinary teams has led to the development of groundbreaking technologies.

Conclusion:

In conclusion, Usman Shabon's relentless pursuit of innovation and his passion for creating solutions to complex problems have solidified his position as a visionary inventor in the tech industry. His contributions continue to inspire the next generation of inventors and pave the way for a more technologically advanced future.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]